

SCARD Pool report for 01-01-2005 to 31-12-2005

| | | | |
|---------------------|-----------------------------|-----|---------|
| Participants | Doctors | 9 | |
| | Patients | 211 | |
| Specimens | New lesions | 351 | 82.59% |
| | Previously biopsied lesions | 74 | 17.41% |
| | Total lesions | 425 | 100.00% |

Breakdown of new versus previously biopsied specimens


| | |
|--|--------|
| Percentage of new lesions tested which were malignant | 57.56% |
| Percentage of Definitively excised lesions that were malignant | 60.62% |
| Lesions tested to find one melanoma (NNT) | 6.20 |
| Percentage of lesions tested for NMSC which were NMSC | 69.37% |
| Ratio of New BCCs : New Melanomas | 12:1 |

Accuracy
Diagnostic sensitivity

| | |
|-----------|---------------|
| Melanomas | 90.00% of 10 |
| All NMSC | 98.40% of 188 |
| BCCs | 97.48% of 119 |
| SCCs | 73.53% of 68 |

Positive predictive value


| | |
|-----------|---------------|
| Melanomas | 75.00% of 12 |
| All NMSC | 88.10% of 210 |
| BCCs | 55.24% of 210 |
| SCCs | 78.13% of 64 |

Adequacy
Percentage of definitively managed malignant cases where surgical margins were adequate

| | |
|---------------------------|---------------|
| BCC | 94.34% of 53 |
| IEC/Bowens disease | 100.00% of 11 |
| SCC | 82.76% of 29 |
| Keratoacanthoma | 100.00% of 1 |
| Melanoma - in situ | 100.00% of 5 |
| Melanoma - invasive | 0% of 0 |
| Melanoma - invasive > 1mm | 100.00% of 1 |
| Other malignant | 0% of 0 |

Lesion Breakdown
Histological Diagnosis

| | | |
|-----------------------------|----|--------|
| BCC (unspecified type) | 30 | 8.52% |
| BCC - Superficial | 29 | 8.24% |
| BCC - Nodular/Solid | 49 | 13.92% |
| BCC - Aggressive | 11 | 3.13% |
| IEC/Bowens disease | 25 | 7.10% |
| SCC | 42 | 11.93% |
| Keratoacanthoma | 1 | 0.28% |
| Pinkus Fibroepithelioma | 0 | 0% |
| Merkel cell tumour | 0 | 0% |
| Other malignant | 1 | 0.28% |
| NMSC Metastasis | 0 | 0% |
| Melanoma - in situ | 6 | 1.70% |
| Melanoma - invasive | 2 | 0.57% |
| Melanoma - invasive > 1mm | 2 | 0.57% |
| Melanoma - metastasis | 0 | 0% |
| MELTUMP | 0 | 0% |
| Naevus - other | 13 | 3.69% |
| Naevus - dysplastic/Clark | 21 | 5.97% |
| Naevus - blue | 2 | 0.57% |
| Naevus - Spitz/Reed | 0 | 0% |
| Naevus - Compound | 0 | 0% |
| Solar keratosis | 24 | 6.82% |
| Solar lentigo | 1 | 0.28% |
| Seborrhoeic keratosis | 41 | 11.65% |
| Lentigo Simplex | 0 | 0% |
| Lichenoid keratosis (LPLK) | 0 | 0% |
| Dermatofibroma | 3 | 0.85% |
| Sebaceous gland hyperplasia | 1 | 0.28% |
| Benign cyst | 11 | 3.13% |
| Other benign | 29 | 8.24% |
| Histology Pending | 1 | 0.28% |



| |
|--------------------------------|
| BCC - 34.59% |
| IEC - 7.27% |
| SCC - 12.21% |
| Keratoacanthoma - 0.29% |
| Other malignant - 0.29% |
| Melanoma - 2.91% |
| Naevus - 10.47% |
| Solar keratosis - 6.98% |
| Solar lentigo - 0.29% |
| Seborrhoeic keratosis - 11.92% |
| Lichenoid keratosis - 0.00% |
| Dermatofibroma - 0.87% |
| Sebaceous gland - 0.29% |
| Benign cyst - 3.20% |
| Other benign - 8.43% |

Procedures
Definitive Surgical Management used to exclude melanoma

| | | |
|-----------------------|----|--------|
| Ellipse | 37 | 94.87% |
| Flap | 0 | 0% |
| Graft - SSG | 0 | 0% |
| Graft - FTSG | 0 | 0% |
| No Closure | 0 | 0% |
| Shave/Saucerisation | 0 | 0% |
| Curettage & Cautery | 1 | 2.56% |
| Liquid N2 freeze/thaw | 0 | 0% |
| PDT | 0 | 0% |
| Imiquimod | 0 | 0% |
| 5 FU cream | 0 | 0% |
| GP referral | 0 | 0% |
| Specialist referral | 1 | 2.56% |
| Other | 0 | 0% |

Biopsy used to exclude melanoma

| | | |
|-----------------|----|--------|
| Punch - sample | 6 | 25.00% |
| Shave - sample | 5 | 20.83% |
| Incisional | 0 | 0% |
| Punch - removal | 1 | 4.17% |
| Shave - removal | 0 | 0% |
| Excisional | 12 | 50.00% |
| Curettage | 0 | 0% |
| Other | 0 | 0% |

Breakdown of definitive management procedures for malignant conditions

| | | |
|-----------------------|-----|--------|
| Ellipse | 107 | 56.32% |
| Flap | 3 | 1.58% |
| Graft - SSG | 0 | 0% |
| Graft - FTSG | 0 | 0% |
| No Closure | 0 | 0% |
| Shave/Saucerisation | 1 | 0.53% |
| Curettage & Cautery | 19 | 10.00% |
| Liquid N2 freeze/thaw | 0 | 0% |
| PDT | 1 | 0.53% |
| Imiquimod | 17 | 8.95% |
| 5 FU cream | 1 | 0.53% |
| GP referral | 0 | 0% |
| Specialist referral | 41 | 21.58% |
| Other | 0 | 0% |

Breakdown of definitive management procedures for benign conditions

| | | |
|-----------------------|----|--------|
| Ellipse | 42 | 67.74% |
| Flap | 0 | 0% |
| Graft - SSG | 0 | 0% |
| Graft - FTSG | 0 | 0% |
| No Closure | 0 | 0% |
| Shave/Saucerisation | 0 | 0% |
| Liquid N2 freeze/thaw | 1 | 1.61% |
| 5 FU cream | 2 | 3.23% |
| GP referral | 0 | 0% |
| Specialist referral | 1 | 1.61% |
| Other | 0 | 0% |

Procedures (continued)

Percentage of procedures/closures that were complex

| | |
|--|----------|
| Complex Closures | 0% of 73 |
| Complex Closures (inc Curettage & Cautery) | 0% of 87 |

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

| | | |
|---------------|---|--------------|
| Nose | 0 | 0% of 24 |
| Lip | 0 | 0% of 1 |
| Ear | 0 | 0% of 16 |
| Eyelid | 0 | 0% of 4 |
| Other face | 1 | 1.79% of 56 |
| Scalp | 1 | 9.09% of 11 |
| Neck | 0 | 0% of 15 |
| Shoulder | 1 | 5.88% of 17 |
| Chest | 0 | 0% of 22 |
| Abdomen | 1 | 33.33% of 3 |
| Genitalia | 0 | 0% of 3 |
| Back | 2 | 3.70% of 54 |
| Buttock | 0 | 0% of 0 |
| Arm | 2 | 12.50% of 16 |
| Forearm | 1 | 4.00% of 25 |
| Hand Dorsal | 0 | 0% of 20 |
| Hand Palmar | 0 | 0% of 0 |
| Finger Dorsal | 0 | 0% of 3 |
| Finger Nail | 0 | 0% of 0 |
| Finger Palmar | 0 | 0% of 0 |
| Thigh | 0 | 0% of 5 |
| Leg | 1 | 2.00% of 50 |
| Foot Dorsal | 0 | 0% of 2 |
| Foot Plantar | 0 | 0% of 4 |
| Toe Dorsal | 0 | 0% of 0 |
| Toe Nail | 0 | 0% of 0 |
| Toe Plantar | 0 | 0% of 0 |
| Palm Or Sole | 0 | 0% of 0 |

